Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy

Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy

Abstract Azacitidine (AZA) is a DNA methyltransferase inhibitor and epigenetic modulator that can be an effective agent in combination with chemotherapy for patients with high‐risk acute myeloid leukemia (AML). However, biological factors driving the therapeutic response of such hypomethylating agen...

Full description

Bibliographic Details
Main Authors: Guanghao Liang, Linchen Wang, Qiancheng You, Kirk Cahill, Chuanyuan Chen, Wei Zhang, Noreen Fulton, Wendy Stock, Olatoyosi Odenike, Chuan He, Dali Han
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Advanced Science
Subjects:
5hmC
acute myeloid leukemia (AML)
azacitidine
biomarkers
machine learning
Online Access:https://doi.org/10.1002/advs.202300445

Internet

https://doi.org/10.1002/advs.202300445

Similar Items